36
Participants
Start Date
September 22, 2008
Primary Completion Date
January 31, 2013
Study Completion Date
January 31, 2013
Bevacizumab
Given IV
Laboratory Biomarker Analysis
Correlative studies
Memorial Sloan-Kettering Cancer Center, New York
Abington Memorial Hospital, Abington
Fox Chase Cancer Center, Philadelphia
Duke University Medical Center, Durham
Carolinas Medical Center/Levine Cancer Institute, Charlotte
Northeast Georgia Medical Center-Gainesville, Gainesville
University of Mississippi Medical Center, Jackson
Ohio State University Comprehensive Cancer Center, Columbus
Riverside Methodist Hospital, Columbus
Lake University Ireland Cancer Center, Mentor
Case Western Reserve University, Cleveland
MetroHealth Medical Center, Cleveland
Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
Hillcrest Hospital Cancer Center, Mayfield Heights
Cleveland Clinic Foundation, Cleveland
Miami Valley Hospital, Dayton
University of Iowa/Holden Comprehensive Cancer Center, Iowa City
University of Minnesota/Masonic Cancer Center, Minneapolis
Hinsdale Hematology Oncology Associates Incorporated, Hinsdale
Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale
Northwestern University, Chicago
University of Chicago Comprehensive Cancer Center, Chicago
Nebraska Methodist Hospital, Omaha
University of Oklahoma Health Sciences Center, Oklahoma City
Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa
Parkland Memorial Hospital, Dallas
UT Southwestern/Simmons Cancer Center-Dallas, Dallas
M D Anderson Cancer Center, Houston
University of Colorado Hospital, Aurora
Los Angeles County-USC Medical Center, Los Angeles
USC / Norris Comprehensive Cancer Center, Los Angeles
Hartford Hospital, Hartford
The Hospital of Central Connecticut, New Britain
Massachusetts General Hospital Cancer Center, Boston
University of Massachusetts Memorial Health Care, Worcester
University of Massachusetts Medical School, Worcester
Collaborators (1)
NRG Oncology
OTHER
National Cancer Institute (NCI)
NIH